Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties
US6846802B2 · kind B2 · utility
65Cited by
1References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 3, 2001 |
| Grant date | Jan 25, 2005 |
| Priority date | — |
| Expiry date | Jul 6, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention discloses novel macrocyclic compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such macrocycles as well as methods of using them to treat disorders associated with the HCV protease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.